Biological Activity of a Novel Nonpeptide Antagonist to the Interleukin-6 Receptor 20S,21-Epoxy-resibufogenin-3-formate
- 1 October 2002
- journal article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET) in Journal of Pharmacology and Experimental Therapeutics
- Vol. 303 (1), 104-109
- https://doi.org/10.1124/jpet.102.036137
Abstract
Interleukin (IL)-6 is a key mediator in the regulation and coordination of the immune response and participates in pathogenesis of cancer cachexia, autoimmune disease, and postmenopausal osteoporosis. In the course of a screening program aimed at IL-6 inhibitor from natural products, we isolated 20S,21-epoxy-resibufogenin-3-formate (ERBF) from bufadienolide and examined the effect of ERBF on activities of various cytokines. ERBF dose dependently suppressed IL-6 activity and caused a parallel rightward shift of dose-response curves to IL-6 at concentrations of 0.03 to 10 ng/ml. Analysis of data yields a pA2 of 5.12 and a slope of 0.99. Selectivity of ERBF on activity of cytokines was examined using cytokine-dependent cell lines. ERBF did not affect IL-2-dependent growth of CTLL-2 cells, IL-3-dependent growth of Baf3 cells, or tumor necrosis factor (TNF)α-induced growth suppression in TNFα-sensitive L929 cells. ERBF also did not affect IL-4-stimulated expression of FcεR II receptor (CD23) in U-937 cells, the IL-8-induced chemotaxis of human neutrophils, or nerve growth factor-stimulated neuronal differentiation in PC-12 cells. In contrast, ERBF dose dependently suppressed IL-6-induced neuronal differentiation in PC-12 cells. Furthermore, ERBF suppressed only IL-6-induced osteoclast formation without affecting osteoclast formation induced by IL-11, leukemia inhibitory factor, and 1α,25-dihydroxyvitamin D3. In receptor binding assay, unbound (free) IL-6 was increased in a dose-dependent manner by pretreatment with ERBF on IL-6 receptor (IL-6R), suggesting that ERBF suppresses binding of IL-6 to IL-6R. These results clearly indicate that ERBF is a novel specific small molecule to show IL-6 receptor antagonist activity.Keywords
This publication has 41 references indexed in Scilit:
- Macrosphelide B Suppressed Metastasis through Inhibition of Adhesion of sLex/E-Selectin MoleculesBiochemical and Biophysical Research Communications, 2002
- Regulation of the gp80 and gp130 subunits of the IL-6 receptor by sex steroids in the murine bone marrow.JCI Insight, 1997
- Relative and Absolute Stereochemistries and Total Synthesis of (+)-Macrosphelides A and B, Potent, Orally Bioavailable Inhibitors of Cell−Cell AdhesionJournal of the American Chemical Society, 1997
- Influence of Interleukin-6 (IL-6) Dimerization on Formation of the High Affinity Hexameric IL-6·Receptor ComplexPublished by Elsevier ,1996
- Parathyroid hormone related protein and interleukin-6 mRNA expression in larynx and renal cell carcinomas from normocalcaemic and hypercalcaemic patients.Journal of Clinical Pathology, 1995
- LIFRβ and gp130 as Heterodimerizing Signal Transducers of the Tripartite CNTF ReceptorScience, 1993
- The IL-6 Signal Transducer, gp130: an Pncostatin M Receptor and Affinity Converter for the LIF ReceptorScience, 1992
- Preparation and characterization of plasma membrane vesicles from human polymorphonuclear leukocytesJournal of Cellular Physiology, 1989
- Soluble cytokine receptors are present in normal human urine.The Journal of Experimental Medicine, 1989
- Current Concepts of B Cell ModulationInternational Reviews of Immunology, 1989